| Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for … C Carroll, S Hummel, J Leaviss, S Ren, JW Stevens, A Cantrell, ... Journal of British Surgery 101 (9), 1040-1052, 2014 | 158 | 2014 |
| A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and … CJ Morrell, P Sutcliffe, A Booth, J Stevens, A Scope, M Stevenson, ... Health Technology Assessment 20 (37), 1-414, 2016 | 151 | 2016 |
| Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation. C Carroll, S Hummel, J Leaviss, S Ren, JW Stevens, E Everson-Hock, ... Health Technology Assessment (Winchester, England) 17 (48), i-xvi, 1, 2013 | 130 | 2013 |
| Extrapolating survival from randomized trials using external data: a review of methods C Jackson, J Stevens, S Ren, N Latimer, L Bojke, A Manca, L Sharples Medical decision making 37 (4), 377-390, 2017 | 119 | 2017 |
| Prehospital noninvasive ventilation for acute respiratory failure: systematic review, network meta‐analysis, and individual patient data meta‐analysis S Goodacre, JW Stevens, A Pandor, E Poku, S Ren, A Cantrell, V Bounes, ... Academic Emergency Medicine 21 (9), 960-970, 2014 | 101 | 2014 |
| What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. J Leaviss, W Sullivan, S Ren, E Everson-Hock, M Stevenson, JW Stevens, ... Health Technology Assessment (Winchester, England) 18 (33), 1-120, 2014 | 94 | 2014 |
| Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. A Pandor, P Thokala, S Goodacre, E Poku, JW Stevens, S Ren, A Cantrell, ... Health technology assessment 19 (42), 1-102, 2015 | 73 | 2015 |
| Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. J Leaviss, S Davis, S Ren, J Hamilton, A Scope, A Booth, A Sutton, ... Health technology assessment (Winchester, England) 24 (46), 1, 2020 | 50 | 2020 |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and … R Archer, P Tappenden, S Ren, MS James, R Harvey, H Basarir, ... Health Technoogyl Assessment 20, 2016 | 49 | 2016 |
| Phosphodiesterase type 5 inhibitors for premature ejaculation: a systematic review and meta-analysis M Martyn-St James, K Cooper, S Ren, E Kaltenthaler, K Dickinson, ... European urology focus 3 (1), 119-129, 2017 | 40 | 2017 |
| How uncertain is the survival extrapolation? A study of the impact of different parametric survival models on extrapolated uncertainty about hazard functions, lifetime mean … B Kearns, J Stevens, S Ren, A Brennan Pharmacoeconomics 38, 193-204, 2020 | 35 | 2020 |
| Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US P Thokala, M Stevenson, VM Kumar, S Ren, AG Ellis, RH Chapman Cost Effectiveness and Resource Allocation 18, 1-12, 2020 | 29 | 2020 |
| Assurance calculations for planning clinical trials with time‐to‐event outcomes S Ren, JE Oakley Statistics in Medicine 33 (1), 31-45, 2014 | 29 | 2014 |
| A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of … P Tappenden, S Ren, R Archer, R Harvey, MMS James, H Basarir, ... Pharmacoeconomics 34, 1023-1038, 2016 | 27 | 2016 |
| Incorporating genuine prior information about between-study heterogeneity in random effects pairwise and network meta-analyses S Ren, JE Oakley, JW Stevens Medical Decision Making 38 (4), 531-542, 2018 | 26 | 2018 |
| How to appropriately extrapolate costs and utilities in cost-effectiveness analysis L Bojke, A Manca, M Asaria, R Mahon, S Ren, S Palmer Pharmacoeconomics 35 (8), 767-776, 2017 | 22 | 2017 |
| Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics S Sadler, M Holmes, S Ren, S Holden, S Jha, P Thokala BJGP open 1 (3), 2017 | 20 | 2017 |
| Vedolizumab for the treatment of adults with moderate-to-severe active ulcerative colitis: an evidence review group perspective of a NICE single technology appraisal M Essat, P Tappenden, S Ren, A Bessey, R Archer, R Wong, A Lobo, ... Pharmacoeconomics 34, 245-257, 2016 | 18 | 2016 |
| R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study R Hart, D Burns, B Ramaekers, S Ren, D Gladwell, W Sullivan, N Davison, ... PharmacoEconomics 38, 765-776, 2020 | 17 | 2020 |
| Living health technology assessment: issues, challenges and opportunities P Thokala, T Srivastava, R Smith, S Ren, MD Whittington, J Elvidge, ... PharmacoEconomics 41 (3), 227-237, 2023 | 16 | 2023 |
